NOT FOR HUMAN OR ANIMAL CONSUMPTION
10mg Mots-c C₈₉H₁₅₂N₂₄O₂₂S₂ + 20mg Reterutide C₂₂₁H₃₄₂N₄₆O₆₈.

COA (Certificate of Analysis) Rets + Mots C
We add each element count:
Carbon (C)
89+221=310
Hydrogen (H)
152+342=494
Nitrogen (N)
24+46=70
Oxygen (O)
22+68=90
Sulfur (S)
2+0=2
Conceptual Research – Stacking MOTS‑c with retatrutide is mechanistically complementary: MOTS‑c works at the mitochondrial/AMPK level, while retatrutide drives powerful receptor‑level appetite and energy‑expenditure changes via GLP‑1/GIP/glucagon agonism.

How each worksMOTS‑cMitochondria‑derived peptide that activates AMPK via inhibition of the folate cycle and de novo purine synthesis, upregulating PGC‑1α, mitochondrial biogenesis, and improving insulin sensitivity and glucose uptake in skeletal muscle.Reduces inflammation and ROS, improves exercise capacity, and synergises with training to enhance metabolic flexibility.RetatrutideTriple agonist at GLP‑1, GIP, and glucagon receptors; suppresses appetite, slows gastric emptying, enhances insulin secretion, and increases energy expenditure via glucagon‑mediated thermogenesis.In phase 2, produced ≈17–24% weight loss over ~48 weeks and significantly reduced liver fat and ALT, indicating strong effects on obesity and NAFLD.Theoretical synergy of the stackDifferent levels of action:Retatrutide: hormonal, receptor‑level control of hunger, insulin, and energy expenditure.MOTS‑c: intracellular AMPK/PGC‑1α axis, improving muscle glucose disposal, mitochondrial efficiency, and exercise response.Potential combined benefits:Greater fat loss and better preservation of lean mass by pairing strong caloric‑intake reduction (retatrutide) with improved muscle oxidative capacity and insulin sensitivity (MOTS‑c).Improved long‑term metabolic resilience: MOTS‑c may counteract inactivity‑related mitochondrial downregulation and support endurance so patients can tolerate and benefit more from exercise while on retatrutide.Possible help with “GLP‑1 fatigue”: some clinicians speculate MOTS‑c may help sustain weight‑loss response and metabolic health alongside GLP‑1‑based drugs, though this is extrapolated and mostly anecdotal.Risks, unknowns, and cautionsEvidence gap:There are no controlled human trials specifically on MOTS‑c + retatrutide; any stacking rationale is extrapolated from separate data on MOTS‑c and triple agonists…Overlapping effects to monitor:Hypoglycaemia risk is low but conceivable in very hypocaloric states because both improve insulin sensitivity/glucose handling; monitor fasting glucose and symptoms.GI side‑effects (nausea, vomiting) are driven by retatrutide; MOTS‑c generally has mild reported adverse events in early studies, but long‑term safety is unknown.Regulatory / practical:Retatrutide is still in late‑stage trials; access is typically via studies or very controlled channels..MOTS‑c is research‑only, with preclinical/early‑phase human data and no formal approval for metabolic disease

Legal and Safety Information;
Quantum Peptides products are provided exclusively for laboratory research and educational use.
They are not approved for human or veterinary applications.
These materials are not intended to diagnose, treat, cure, or prevent any medical condition.
All use must adhere to applicable laws and regulatory requirements.
“The photo is for illustration purposes only and includes as much product information as possible.

Bottle labels wrap around the container and may vary slightly in design & between batches as part of our anti‑counterfeiting measures.”